Please use this identifier to cite or link to this item:
Title: Targeted Next-Generation Sequencing in a Large Cohort of Genetically Undiagnosed Patients with Neuromuscular Disorders in Spain
Author: González Quereda, Lidia
Rodríguez, Maria Jose
Diaz Manera, Jordi
Alonso Pérez, Jorge
Gallardo, Eduard
Nascimento, Andrés
Ortez, Carlos
Natera de Benito, Daniel
Olivé i Plana, Montserrat
González Mera, Laura
López de Munain, Adolfo
Zulaica, Miren
Poza, Juan Jose
Jerico, Ivonne
Tome, Laura
Riera, Pau
Milisenda, José
Sánchez, Aurora
Garrabou Tornos, Glòria
Llano, Isabel
Madruga Garrido, Marcos
Gallano, Pia
Keywords: Malalties neuromusculars
Malalties musculars
Neuromuscular diseases
Muscular diseases
Issue Date: 1-May-2020
Publisher: MDPI
Abstract: The term neuromuscular disorder (NMD) includes many genetic and acquired diseases and differential diagnosis can be challenging. Next-generation sequencing (NGS) is especially useful in this setting given the large number of possible candidate genes, the clinical, pathological, and genetic heterogeneity, the absence of an established genotype-phenotype correlation, and the exceptionally large size of some causative genes such asTTN,NEBandRYR1.We evaluated the diagnostic value of a custom targeted next-generation sequencing gene panel to study the mutational spectrum of a subset of NMD patients in Spain. In an NMD cohort of 207 patients with congenital myopathies, distal myopathies, congenital and adult-onset muscular dystrophies, and congenital myasthenic syndromes, we detected causative mutations in 102 patients (49.3%), involving 42 NMD-related genes. The most common causative genes,TTN and RYR1, accounted for almost 30% of cases. Thirty-two of the 207 patients (15.4%) carried variants of uncertain significance or had an unidentified second mutation to explain the genetic cause of the disease. In the remaining 73 patients (35.3%), no candidate variant was identified. In combination with patients' clinical and myopathological data, the custom gene panel designed in our lab proved to be a powerful tool to diagnose patients with myopathies, muscular dystrophies and congenital myasthenic syndromes. Targeted NGS approaches enable a rapid and cost-effective analysis of NMD- related genes, offering reliable results in a short time and relegating invasive techniques to a second tier.
Note: Reproducció del document publicat a:
It is part of: Genes, 2020, vol. 11, num. 5
Related resource:
Appears in Collections:Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))
Articles publicats en revistes (Medicina)
Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)

Files in This Item:
File Description SizeFormat 
Gonzalez-QueredaL.pdf749.52 kBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.